Ps949 Inotuzumab Ozogamicin (ino) Treatment in Patients With Relapsed/refractory Acute Lymphoblastic Leukemia (r/r All): Outcomes of Patients Treated in Salvage One With a Long Duration of First Remission
Year: 2019
Type: conference-abstract
Abstract: Background: In R/R ALL, data are limited supporting targeted therapies like InO as first salvage in patients (pts) who achieved a long duration of first complete remission (CR1). InO, a calicheamicin‐conjugated antibody, targets CD22 on ALL blasts. Aims: Here we report outcomes in pts with ALL in first salvage (S1) who had a long CR1 before receiving InO vs standard of care chemotherapy (SC). image Methods: Adults with CD22+ R/R ALL, stratified by salvage and length of remission (CR1 ≥ or <12 mos), were randomized to receive InO (n = 164) or SC (n = 162). Methods were previously described (Kantarjian et al, NEJM 2016), with data shown up to the last patient last visit (January 4, 2017). Outcomes including complete remission (CR)/CR with incomplete hematologic recovery (CRi) and overall survival (OS) were determined for S1 pts who achieved CR1 ≥ 12 mos and CR1 ≥ 18 mos. Results: For S1 pts with CR1 ≥ 12 mos or CR1 ≥ 18 mos, InO and SC arms had generally comparable baseline characteristics. For S1 pts with CR1 ≥ 12 mos and CR1 ≥ 18 mos, fewer pts had received a prior stem cell transplant in the InO vs SC arm (10.4% vs 25.0% and 9.7% vs 21.4%). For S1 pts with CR1 ≥ 12 mos and CR1 ≥ 18 mos respectively, InO vs SC treatment led to a higher CR/CRi rate (85.4% vs 27.5% [P < 0.0001] and 83.9% vs 32.1% [P < 0.0001]) and improved OS (HR = 0.547 [P = 0.0086] and 0.504 [P = 0.0163]), with veno‐occlusive liver disease reported in 12.5% and 12.9% of InO pts. Summary/Conclusion: Improved outcomes were seen with InO vs SC among S1 pts who had a long first complete remission (CR1 ≥ 12 mos or CR1 ≥ 18 mos), supporting the benefit of InO vs SC in this population.
Source: HemaSphere
Institutions: Great Ormond Street Hospital, University Hospital Münster, The University of Texas MD Anderson Cancer Center, Cleveland Clinic, Dana-Farber Cancer Institute, University of Chicago, University of California, Irvine Medical Center, University of Washington, Fred Hutch Cancer Center, Pfizer (United States), Royal Aberdeen Children's Hospital, Pfizer (Germany), Royal Marsden Hospital
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,480
OpenAlex ID: W2949284331